FATE Q2 2025 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-71.8% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$37M-1938.5% margin

Net Income

-$34M-1786.6% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+17.1%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$26M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$372M

Total Liabilities

$110M

Stockholders' Equity

$261M

Cash & Equivalents

$41M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$7M	-71.8%
Gross Profit	$2M	$2M	-7.0%
Operating Income	-$37M	-$45M	+18.0%
Net Income	-$34M	-$38M	+11.3%